Vertex Pharmaceuticals (VRTX) Short term Debt (2009 - 2016)

Vertex Pharmaceuticals' Short term Debt history runs 6 years deep, the most recent figure standing at $75.0 million for Q4 2016.

• On a quarterly basis, Short term Debt changed N/A year-over-year to $75.0 million in Q4 2016; TTM through Dec 2016 was $75.0 million, a N/A change from a year earlier, with the FY2016 full-year figure at $75.0 million, changed N/A from the prior year.
• Short term Debt eased to $75.0 million in Q4 2016 per VRTX's latest filing, from $297.8 million in the prior quarter.
• Across five years, Short term Debt topped out at $297.8 million in Q3 2016 and bottomed at $14.2 million in Q4 2014.
• The 3-year median for Short term Debt is $75.0 million (2016), against an average of $118.0 million.
• Biggest YoY gain for Short term Debt was 416.82% in 2016; the steepest drop was 412.68% in 2016.
• Year by year, Short term Debt stood at $14.2 million in 2014, then soared by 201.8% to $42.9 million in 2015, then jumped by 74.94% to $75.0 million in 2016.
• Per Business Quant, the three latest VRTX Short term Debt figures stand at $75.0 million (Q4 2016), $297.8 million (Q3 2016), and $221.6 million (Q2 2016).